prikaz prve stranice dokumenta An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment
Prostaglandins, Leukotrienes and Essential Fatty Acids, 200 (2024); 102604. https://doi.org/10.1016/j.plefa.2023.102604
Nadalin, Sergej; Zatković, Lena; Peitl, Vjekoslav; Karlović, Dalibor; Vilibić, Maja; Silić, Ante; Dević Pavlić, Sanja; Buretić-Tomljanović, Alena

Cite this document

Nadalin, S., Zatković, L., Peitl, V., Karlović, D., Vilibić, M., Silić, A. ... Buretić Tomljanović, A. (2024). An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, 200.. doi: 10.1016/j.plefa.2023.102604

Nadalin, Sergej, et al. "An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment." Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 200, 2024. https://doi.org/10.1016/j.plefa.2023.102604

Nadalin, Sergej, Lena Zatković, Vjekoslav Peitl, Dalibor Karlović, Maja Vilibić, Ante Silić, Sanja Dević Pavlić and Alena Buretić Tomljanović. "An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment." Prostaglandins, Leukotrienes and Essential Fatty Acids 200 (2024). https://doi.org/10.1016/j.plefa.2023.102604

Nadalin, S., et al. (2024) 'An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment', Prostaglandins, Leukotrienes and Essential Fatty Acids, 200. doi: 10.1016/j.plefa.2023.102604

Nadalin S, Zatković L, Peitl V, Karlović D, Vilibić M, Silić A, and sur.. An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids [Internet]. 2024 January [cited 2024 November 29];200. doi: 10.1016/j.plefa.2023.102604

S. Nadalin, et al., "An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment", Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 200, January 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:091129. [Accessed: 29 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)An association between PPARα-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment
AuthorSergej Nadalin
AuthorLena Zatković
AuthorVjekoslav Peitl
AuthorDalibor Karlović
AuthorMaja Vilibić
AuthorAnte Silić
AuthorSanja Dević Pavlić
AuthorAlena Buretić-Tomljanović
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Biology and Medical Genetics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Psychiatry
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Human Genetics, Genomics and Proteomics
Abstract (english)
Peroxisome proliferator-activated receptor alpha (PPARα) and antipsychotic medications both influence poly unsaturated fatty acids (PUFA) homeostasis, and thus PPARα polymorphism may be linked to antipsychotic treatment response. Here we investigated whether the functional leucine 162 valine (L162V) polymorphism in PPARα influenced antipsychotic treatment in a group of psychosis patients (N = 186), as well as in a patient subgroup with risperidone, paliperidone, or combination treatment (N = 65). Antipsychotic-naïve first-episode patients and nonadherent chronic individuals were genotyped by polymerase chain reaction analysis. At base line, and after 8 weeks of treatment with various antipsychotic medications, we assessed the patients’ Positive and Negative Syndrome Scale (PANSS) scores; PANSS factors; and metabolic syndrome-related parameters, including fasting plasma lipid and glucose levels, and body mass index. In the total patient group, PPARα polymorphism did not affect PANSS psychopathology or metabolic parameters. However, in the subgroup of patients with risperidone, paliperidone, or combination treatment, PPARα polymorphism influenced changes in plasma LDL cholesterol. Specifically, compared to PPARα-L162L homozygous patients, PPARα-L162V hetero zygous individuals exhibited significantly higher increases of LDL cholesterol levels after antipsychotic treat ment. The PPARα polymorphism had a strong effect size, but a relatively weak contribution to LDL cholesterol level variations (~12.8 %).
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleProstaglandins, Leukotrienes and Essential Fatty Acids
Numberingvol. 200, 102604
p-ISSN0952-3278
DOIhttps://doi.org/10.1016/j.plefa.2023.102604
URN:NBNurn:nbn:hr:184:091129
Publication2024-01
ProjectNumber: uniri-biomed-18-251
Title (croatian): Genetički i biokemijski biljezi metabolizma membranskih fosfolipida i masnih kiselina kao predskazatelji odgovora na antipsihotičnu terapiju u bolesnika s psihotičnom epizodom
Title (english): Genetic and biochemical markers of the membrane phospholipid and fatty acid metabolism as predictors of treatment response to antipsychotic therapy in patients with psychotic episodes
Leader: Alena Buretić-Tomljanović
Jurisdiction: Croatia
Funding stream: Nema
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S095232782300073X
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2024-02-13 07:56:01